Camurus AB
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 1991-01-01
- Employees
- 213
- Market Cap
- -
- Website
- http://www.camurus.com
Clinical Trials
46
Trial Phases
5 Phases
Drug Approvals
2
Clinical Trials
Distribution across different clinical trial phases (43 trials with phase data)• Click on a phase to view related trials
A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
- Conditions
- Polycystic Liver Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Camurus AB
- Target Recruit Count
- 71
- Registration Number
- NCT05281328
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mount Sinai Hospital, New York, New York, United States
🇺🇸The New York Presbyterian Hospital, New York, New York, United States
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET
- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor
- Interventions
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Camurus AB
- Target Recruit Count
- 332
- Registration Number
- NCT05050942
- Locations
- 🇺🇸
Mayo Clinic Cancer Center (MCCC) - Phoenix, Phoenix, Arizona, United States
🇺🇸UCLA Ahmanson Biological Imaging Center, Santa Monica, California, United States
🇺🇸Rocky Mountain Cancer Centers - Denver - Midtown, Denver, Colorado, United States
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
- Conditions
- Acromegaly
- Interventions
- Drug: CAM2029 (octreotide subcutaneous depot)
- First Posted Date
- 2019-10-14
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Camurus AB
- Target Recruit Count
- 135
- Registration Number
- NCT04125836
- Locations
- 🇪🇸
Hospital Universitario Vall d'Hebron, Barcelona, Spain
🇺🇸UCLA Department of Medicine Division of Endocrinology, Los Angeles, California, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
- Conditions
- Acromegaly
- Interventions
- Drug: CAM2029 (octreotide subcutaneous depot)Drug: Matching placebo
- First Posted Date
- 2019-09-03
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Camurus AB
- Target Recruit Count
- 72
- Registration Number
- NCT04076462
- Locations
- 🇺🇸
UCLA Department of Medicine Division of Endocrinology, Los Angeles, California, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Prufen Clinical Research LLC, Miami, Florida, United States
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
- Conditions
- Neuroendocrine TumorsAcromegaly
- Interventions
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Camurus AB
- Target Recruit Count
- 12
- Registration Number
- NCT02299089
- Locations
- 🇫🇷
Hospices Civils de Lyon, Bron, France
🇫🇷CHU Rouen, Hôpital Charles Nicolle, Rouen cedex, France
🇩🇪Abteilung: Klinische Studien, Bad Berka, Germany
- Prev
- 1
- 2
- Next